Chengdu Kanghong Pharmaceutical (SHE:002773) obtained drug registration from China's medical products regulator for 2- and 4-milligram dosages of perapanel tablets.
The drug is used to treat partial-onset and primary generalized tonic-clonic seizures, according to a Friday fling with the Shenzhen bourse.
Shares of the pharmaceutical company were down 1% in recent trade.